5.1. primary diagnosis. 5.1.1. symptoms painless visible haematuria common presenting complaint. presenting symptoms clinical signs include nonvisible haematuria, urgency, dysuria, increased frequency, advanced tumours, pelvic pain symptoms related urinary tract obstruction. 5.1.2. physical examination physical examination include rectal vaginal bimanual palpation. palpable pelvic mass found patients locally-advanced tumours. addition, bimanual examination anaesthesia carried tur bladder tumour (turbt) assess whether palpable mass tumour fixed pelvic wall . however, considering discrepancy bimanual examination pt stage cystectomy (11% clinical overstaging 31% clinical understaging), bimanual examination findings need interpreted caution . 5.1.3. bladder imaging patients bladder mass identified diagnostic imaging technique undergo cystoscopy, biopsy and/or resection histopathological diagnosis staging. due high specificity diagnostic imaging detecting bc, patients imaging positive bc may avoid diagnostic flexible cystoscopy go directly rigid cystoscopy transurethral resection . 5.1.4. urinary cytology examination voided urine bladder washings exfoliated cancer cells high sensitivity high-grade tumours useful indicator cases high-grade malignancy cis. however, positive urinary cytology may originate urothelial tumour located anywhere urinary tract. evaluation cytology specimens hampered low cellular yield, utis, stones intravesical instillations, experienced readers, specificity exceeds 90% . however, negative cytology exclude tumour. known urinary marker specific diagnosis invasive bc . standardised reporting system, ‘paris system’ redefining urinary cytology diagnostic categories updated 2022 : adequacy urine specimens (adequacy);negative high-grade uc (negative);atypical urothelial cells (auc);suspicious high-grade uc (suspicious);high-grade uc (hguc). 5.1.5. cystoscopy ultimately, diagnosis bc made cystoscopy histological evaluation resected tissue. (outpatient) flexible cystoscopy recommended obtain complete image bladder. however, daily practice, bladder tumour visualised unequivocally imaging studies computed tomography (ct), magnetic resonance imaging (mri), ultrasound (us), diagnostic cystoscopy may omitted patient proceed directly turb histological diagnosis resection. procedure, thorough inspection bladder rigid cystoscopy anaesthesia mandatory order miss tumours level bladder neck. careful description cystoscopic findings necessary. include documentation site, size, number, appearance (papillary solid) tumours, well description mucosal abnormalities . use bladder diagram recommended. use pdd could considered t1 high-grade tumour present identify associated cis. presence cis may lead modified treatment plan (see eau guidelines non-muscle-invasive bladder cancer ). photodynamic diagnosis highly sensitive detection cis experienced hands rate false-positive results may similar regular white-light cystoscopy . 5.1.6. transurethral resection invasive bladder tumours goal turb enable histopathological diagnosis staging, requires inclusion bladder muscle resection specimen. case mibc suspected, tumours need (ideally) resected separately parts, include exophytic part tumour, underlying bladder wall detrusor muscle, edges resection area. least deeper part resection specimen must referred pathologist separate labelled container enable making correct diagnosis staging. cases rt considered cis excluded, pdd used . involvement prostatic urethra ducts men bladder tumours reported 1 3 patients . under-reporting possibly also means exact risk known, seems higher tumour located trigone bladder neck, concomitant bladder cis, case multiple tumours . involvement prostatic urethra determined either time primary turb frozen section cystoprostatectomy procedure. frozen section higher negative-predictive value accurate [105-107]. negative urethral frozen section reliably identify patients urethrectomy avoided. however, positive pre-operative biopsy seems limited utility findings reliably associated final margin status . diagnosis urethral tumour cystectomy result urethrectomy could contraindication orthotopic diversion. however, orthotopic diversion denied based positive pre-operative biopsy findings alone frozen section part rc procedure, particularly male patients . 5.1.7. summary evidence guidelines primary assessment presumably invasive bladder tumours summary evidencelecystoscopy necessary diagnosis bladder cancer.1urinary cytology high sensitivity high-grade tumours including carcinoma situ.2bin men, prostatic urethral biopsy includes resection bladder neck verumontanum (between 5 7 o’clock position) using resection loop. case abnormal-looking areas prostatic urethra present time, need biopsied well.2b recommendationsstrength ratingdescribe macroscopic features tumour (site, size, number appearance) mucosal abnormalities cystoscopy. use bladder diagram.strongtake biopsy prostatic urethra cases bladder neck tumour, bladder carcinoma situ present suspected, positive cytology without evidence tumour bladder, abnormalities prostatic urethra visible.strongin men negative prostatic urethral biopsy undergoing subsequent orthotopic neobladder construction, intra-operative frozen section omitted.strongin men prior positive transurethral prostatic biopsy, subsequent orthotopic neobladder construction denied priori, unless intra-operative frozen section distal urethral stump reveals malignancy level urethral dissection.strongin women undergoing subsequent orthotopic neobladder construction, obtain procedural information (including histological evaluation) bladder neck urethral margin, either prior to, time cystectomy.strongin pathology report, specify grade, depth tumour invasion, whether lamina propria muscle tissue present specimen.strong (for general information assessment bladder tumours, see eau guidelines non-muscle-invasive bladder cancer ). 5.1.8. eau-esmo consensus statements management advanced- variant bladder cancer [81-82]* consensus statementdifferentiating urachal non-urachal subtypes adenocarcinoma essential making treatment decisions. *only statements met priori consensus threshold across three stakeholder groups listed(defined ≥ 70% agreement ≤ 15% disagreement, vice versa).